Rheumatic diseases frequently present with insidious onset and non-specific early manifestations, leading to substantial diagnostic delays in primary care. These delays are closely associated with a prolonged subclinical inflammation phase, during which pathogenic immune processes are active yet clinically inapparent. This review aims to synthesize current mechanistic understanding of subclinical inflammation and its role in the concealment of early rheumatic disease.

This narrative review integrates evidence from recent studies investigating the immunological mechanisms underlying subclinical inflammation, with particular focus on rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) as prototypical rheumatic diseases.

Subclinical inflammation represents a state of persistent, low-grade immune activation occurring in the absence of overt clinical signs, structural damage, or marked laboratory abnormalities. This phase is driven primarily by innate immune priming, sterile inflammation, and low-intensity cytokine signaling, which collectively sustain immune dysregulation below conventional diagnostic thresholds. Key mechanistic processes include pattern recognition receptor (e.g., Toll-like receptor) activation, inflammasome signaling, modest but chronic production of pro-inflammatory cytokines (such as TNF-α, IL-1β, and IL-6), and gradual erosion of immune tolerance. These mechanisms precede full adaptive immune engagement, autoantibody maturation, and tissue-specific inflammation, thereby creating a temporal dissociation between molecular pathology and clinical expression. Disease-specific evidence from RA and SLE demonstrates that subclinical inflammation constitutes a common early pathogenic state across diverse rheumatic conditions. Importantly, the heterogeneity and compartmentalization of early immune activation—occurring locally within tissues rather than systemically—explain why routine clinical assessment and standard inflammatory markers (e.g., ESR, CRP) frequently fail to detect active disease in primary care settings.

By integrating current mechanistic insights, this review reframes diagnostic delay as a biologically driven phenomenon rather than merely a limitation of clinical practice. Understanding the mechanisms of subclinical inflammation provides a rational framework for risk-informed recognition and timely referral in primary care, with potential implications for improving long-term outcomes in patients with rheumatic diseases.